Table 1.
Patient characteristics.
| Demographic | All patients N = 222 |
Aromatase Inhibitor (%) N = 162 (72.97) |
Fulvestrant (%) N = 58 (26.13) |
|---|---|---|---|
| Age at CDK Start, y | |||
| Median | 63 | 62 | 66.5 |
| Range | [27, 89] | [27, 84] | [43, 89] |
| <65 | 125 | 99 | 26 |
| ≥65 | 97 | 63 | 32 |
| BMI at CDK start | |||
| Median | 27.85 | 27.8 | 28.1 |
| Range | [15.4, 56.2] | [15.4, 56.2] | [16.3, 47.1] |
| Underweight (<18.5) | 6 | 5 | 1 |
| Normal (18.5-24.9) | 56 | 42 | 13 |
| Overweight (25.0-29.9) | 70 | 49 | 20 |
| Obese (≥30) | 88 | 64 | 24 |
| ECOG at CDK start | |||
| 0 | 126 | 93 | 32 |
| 1 | 75 | 52 | 22 |
| 2 | 13 | 10 | 3 |
| 3 | 1 | 1 | 0 |
| Sex | |||
| Female | 219 | 159 | 58 |
| Male | 3 | 3 | 0 |
| Race/ethnicity | |||
| European | 192 | 145 | 45 |
| Asian | 3 | 1 | 2 |
| African American | 17 | 8 | 9 |
| Hispanic & Latino | 4 | 3 | 1 |
| Other | 2 | 2 | 0 |
| Menopause status at CDK start | |||
| Pre | 34 | 31 | 3 |
| Peri and post | 181 | 128 | 51 |
| Male | 3 | 3 | 0 |
| Smoking status | |||
| Never | 114 | 76 | 36 |
| Former & past | 75 | 60 | 15 |
| Current | 17 | 12 | 5 |
| Visceral status | |||
| Visceral | 103 | 69 | 32 |
| Non-visceral | 119 | 93 | 26 |
| Metastatic status at presentation | |||
| De Novo | 66 | 58 | 8 |
| Recurrent | 156 | 104 | 50 |
| Number of metastatic sites | |||
| 1 | 92 | 69 | 23 |
| 2 | 67 | 44 | 22 |
| ≥3 | 48 | 37 | 10 |
| Prior endocrine therapy | |||
| Yes | 156 | 99 | 55 |
| No | 66 | 63 | 3 |
| Prior chemotherapy | |||
| Yes | 122 | 84 | 37 |
| No | 100 | 78 | 21 |